Literature DB >> 24261148

Stability of captopril in SyrSpend SF.

Christine M Geiger1, Bridget Sorenson, Paul A Whaley.   

Abstract

Captopril is an angiotensin-converting enzyme inhibitor available as a tablet. Patients who are unable to take tablets have led compounding pharmacies to seek alternative dosage forms including solutions and suspensions. The objective of this study was to determine the stability of captopril in sorbitol-free, alcohol-free SyrSpend SF suspending agent. The studied samples were compounded into a 0.8-mg/mL suspension and stored in low-actinic plastic bottles at temperatures between 2 degrees C to 8 degrees C. Six samples were assayed at each time point out to 32 days by a stability-indicating high-performance liquid chromatography method. The samples remained within 90% to 110% of the initial concentration throughout day 14 of the study. Based on the data collected, the beyond- use date of these preparations is 14 days when protected from light and refrigerated.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24261148

Source DB:  PubMed          Journal:  Int J Pharm Compd        ISSN: 1092-4221


  3 in total

1.  Limited Influence of Excipients in Extemporaneous Compounded Suspensions.

Authors:  Eli Dijkers; Valerie Nanhekhan; Astrid Thorissen; Diego Marro; Marta Uriel
Journal:  Hosp Pharm       Date:  2017-07-13

2.  Compounded Nonsterile Preparations and FDA-Approved Commercially Available Liquid Products for Children: A North American Update.

Authors:  Richard H Parrish; Lisa D Ashworth; Raimar Löbenberg; Sandra Benavides; Jeffrey J Cies; Robert B MacArthur
Journal:  Pharmaceutics       Date:  2022-05-10       Impact factor: 6.525

3.  Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions.

Authors:  Hudson C Polonini; Sharlene L Silva; Thalyta R de Almeida; Marcos Antônio F Brandão; Anderson O Ferreira
Journal:  Eur J Hosp Pharm       Date:  2016-03-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.